Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Weigao Blood Purification Products CoSHSE:603014 +0.67%39 Return-on-Tangible-Asset is 5.41% as of Jun. 2026, which is 10% below its 10-year median of 6.04. GuruFocus rates SHSE:603014 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Shandong Weigao Blood Purification Products Co ranks better than 69.37% on this metric.
SHSE:603014's Return-on-Tangible-Asset is ranked better than 69.37% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.92
vs SHSE:603014: 6.03
Shandong Weigao Blood Purification Products Co (SHSE:603014) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Shandong Weigao Blood Purification Products Co Return-on-Tangible-Asset Related Terms
Shandong Weigao Blood Purification Products Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Weigao Blood Purification Products Co Return-on-Tangible-Asset Chart
Shandong Weigao Blood Purification Products Co Annual Data
SHSE:603014 vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Shandong Weigao Blood Purification Products Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Weigao Blood Purification Products Co Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.41% mean?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a Return-on-Tangible-Asset of 5.41% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. This is 10% below median its historical median of 6.04. Over the past decade, Shandong Weigao Blood Purification Products Co's Return-on-Tangible-Asset has ranged from 4.77 to 6.91. According to the industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #261 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 30.6%.
Is Shandong Weigao Blood Purification Products Co's Return-on-Tangible-Asset too high?
Shandong Weigao Blood Purification Products Co's current Return-on-Tangible-Asset of 5.41% is 10% below median its 10-year median of 6.04. Over the past 10 years, this metric has ranged from a low of 4.77 to a high of 6.91. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.92. Shandong Weigao Blood Purification Products Co's value of 5.41% is 488% above this industry median. Based on the distribution chart, Shandong Weigao Blood Purification Products Co ranks #261 out of 852 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shandong Weigao Blood Purification Products Co ranks #261 out of 852 companies for Return-on-Tangible-Asset. This puts Shandong Weigao Blood Purification Products Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.92. Shandong Weigao Blood Purification Products Co's value of 5.41% is 488% above this benchmark. Historically, Shandong Weigao Blood Purification Products Co's own Return-on-Tangible-Asset has ranged from 4.77 to 6.91 over the past decade. While the company's 10-year median is 6.04 vs. the industry median of 0.92, Shandong Weigao Blood Purification Products Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.92, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Weigao Blood Purification Products Co's current Return-on-Tangible-Asset of 5.41% is 488% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Weigao Blood Purification Products Co's current Return-on-Tangible-Asset is 5.41%, which is 10% below median its own 10-year median of 6.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current Return-on-Tangible-Asset of 5.41%. The current Return-on-Tangible-Asset is 5.41%, which is 10% below median its 10-year median of 6.04 and 488% above the Medical Devices & Instruments industry median of 0.92. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current Return-on-Tangible-Asset is 5.41% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603014 has been successfully added to your 
